NEW YORK, Jan 28 (Reuters) - The chief executive of Schering-Plough Corp learned the results of a controversial study involving its big-selling cholesterol drug four days before the company released results to the public, the company said on Monday.
NEW YORK, Jan 28 (Reuters) - The chief executive of Schering-Plough Corp learned the results of a controversial study involving its big-selling cholesterol drug four days before the company released results to the public, the company said on Monday.
